Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FYN | P06241 | 9/20 | 0.50 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | TTK | P33981 | 1/20 | 0.42 |
| ▸ | BRAF | P15056 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.41 |
| ▸ | THRB | P10828 | 1/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | PIP5K1C | O60331 | 1/20 | 0.41 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1945872 | 0.94 | FYN (0.47) | FYNKDM4EALDH1A1SMN1; SMN2MAPT | |
| SCHEMBL1945954 | 0.90 | FYN (0.56) | FYNTTK | |
| SCHEMBL1946149 | 0.87 | FYN (0.47) | FYNKDM4EALDH1A1NPC1RAB9A | |
| SCHEMBL1945329 | 0.84 | FYN (0.70) | FYN | |
| SCHEMBL1945127 | 0.83 | F2RL3 (0.50) | FYNMAPTRXFP1 | |
| SCHEMBL1944969 | 0.83 | F2RL3 (0.50) | FYNKDM4EALDH1A1 | |
| SCHEMBL2250766 | 0.83 | FYN (0.53) | FYNKDM4ESMN1; SMN2MAPTTHRB | |
| SCHEMBL1946366 | 0.83 | FYN (0.53) | FYNKDM4ESMN1; SMN2TTKMAPT | |
| SCHEMBL1946917 | 0.83 | FYN (0.52) | FYNRIPK3 | |
| SCHEMBL15603310 | 0.82 | FYN (0.47) | FYNTTKMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307425-B1 | IMIDAZOTHIADIAZOLES DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-26 | — | — | EP | claimed |
| EP-2307425-B1 | IMIDAZOTHIADIAZOLES DERIVATIVES | MERCK PATENT GMBH (DE) | 2014-03-26 | — | — | EP | disclosed |
| US-8389554-B2 | Imidazothiadiazole derivatives | MERCK Patent Gesellschaft mit beschränkter Haftung (DE) | 2013-03-05 | — | — | US | disclosed |
| US-20110130396-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2011-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110130396-A1 | IMIDAZOTHIADIAZOLE DERIVATIVES | TGFBR1, TGFBR2, IGF1R | FYN 1977/4885RIPK3 469/4885KDM4E 2685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.